Akèy › Limfòm Non-Hodgkin › Texas › Dallas
Etid klinik pou Limfòm Non-Hodgkin nan Dallas, TX
17 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Dallas (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Ap rekriteFaz 1/2
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Ap rekriteFaz 2
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 1
- Baylor University Medical Center, Dallas
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Baylor University Medical Center, Dallas
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Ap rekriteEtid obsèvasyon
- UT Southwestern Medical Center, Dallas
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- UT Southwestern Medical Center, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Ap rekriteFaz 1/2
- University of Texas Southwestern Medical Center, Dallas
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- University of Texas Southwestern, Dallas
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Ap rekriteFaz 1
- UT Southwestern Medical Center, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Ap rekriteEtid obsèvasyon
- Ut Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Dallas
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Ap rekriteEtid obsèvasyon
- University of Texas Southwestern, Dallas
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- University of Texas Southwestern Medical Center, Dallas
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Ap rekriteFaz 1/2
- UT Southwestern Medical Center, Dallas
Etid Limfòm Non-Hodgkin nan lòt vil
- Houston, TX31 etid
- New York City, NY31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Washington, DC18 etid
- Durham, NC16 etid
Lòt etid nan Dallas
- Kansè nan tete55 etid
- Kansè Poumon ki pa ti selil52 etid
- Kansè Metastatik42 etid
- Ensifizyans kadyak42 etid
- Kansè (tout kalite)37 etid
- Kansè pwostat36 etid
- Kansè kolorektal33 etid
- Obèsite30 etid
- Kansè ovè28 etid
- Kansè vejik27 etid
- Kansè poumon27 etid
- Kansè Endomèt24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.